CD20 / MS4A1 (aa 213-297) Protein (His Tag)

Produkt-Information von CD20 / MS4A1 Protein

QC Testing von CD20 / MS4A1 Protein

Purity	> 83 % as determined by SDS-PAGE	SDS-PAGE: CD20 / MS4A1 protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	His
Molecular Mass	The recombinant human CD20 comprises 105 amino acids and has a predicted molecular mass of 12.1 kDa. The apparent molecular mass of the protein is approximately 23 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Formulation	Lyophilized from 0.2μm filtered solution of PBS, pH7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.

Usage Guide von CD20 / MS4A1 Protein

Verwandte Produkte & Themen von CD20 / MS4A1 Protein

Cancer>>Cancer Stem Cell (CSC)>>CD20/MS4A1

Stem Cell>>Hematopoietic Stem Cell (HSC)>>Hematopoietic Stem Cell Marker>>CD20/MS4A1

Immunology>>Cluster of Differentiation>>B Cell CD Antigen>>CD20/MS4A1

Immunology>>Cluster of Differentiation>>Hematopoietic Stem Cell CD Marker>>CD20/MS4A1

Beschreibung von CD20 / MS4A1 Protein

B-lymphocyte antigen CD20, also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is a multi-pass membrane protein which belongs to theMS4A family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed on all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

References

1. Tedder TF. et al.,1988, Proc Natl Acad Sci. 85 (1): 208-12.
2. Cragg MS. et al., 2005, Curr Dir Autoimmun. 8: 140-74.
3. Fang D. et al., 2005, Cancer Res. 65 (20): 9328-37.
4. Teeling JL. et al., 2006, J Immunol. 177: 362-71.

Sino Biological Inc. liefert CD20 / MS4A1 (aa 213-297) Protein (His Tag) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über CD20 / MS4A1 (aa 213-297) Protein (His Tag) lesen Sie bitte: http://www.sinobiological.com/CD20-MS4A1-Protein-g-9063.html